Peter Devuyst
Physician Assistant · Fort Walton Beach, FLNPI 1457369647
Payments from drug & device makers
Across 528 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$1K
- Amgen$840
- CSL Behring$835
- plus $3K from 29 others
What the payments were for
- Consulting fees$240%
- Food & beverage$11,50096%
- Education$4254%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $1,979 |
| GSK | 127 | $1,859 |
| Regeneron Healthcare Solutions, Inc. | 72 | $1,792 |
| Sanofi | 42 | $1,347 |
| Amgen(2 entities) | 41 | $840 |
| CSL Behring | 38 | $835 |
| Grifols USA, LLC | 24 | $525 |
| Insmed, Inc. | 15 | $394 |
| Pharming Healthcare, Inc. | 15 | $301 |
| Novartis | 7 | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $227 |
| Kaleo, Inc. | 13 | $198 |
| Sanofi-aventis U.S. LLC | 2 | $180 |
| Biocryst US Sales Co., LLC | 8 | $177 |
| Pfizer | 6 | $117 |
| Blueprint Medicines Corporation | 4 | $101 |
| Nevro Corp. | 1 | $97 |
| Genentech USA, Inc. | 6 | $94 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $68 |
| Cycle Pharmaceuticals Inc | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $53 |
| Lilly USA, LLC | 2 | $51 |
| Novo Nordisk | 1 | $51 |
| Verona Pharma, Inc. | 2 | $44 |
| Boehringer Ingelheim | 2 | $36 |
| Merck | 2 | $33 |
| Tersera Therapeutics LLC | 2 | $32 |
| Galderma Laboratories, L.p. | 2 | $31 |
| Alk-abello, Inc | 2 | $28 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| ADMA Biomanufacturing LLC | 1 | $24 |
| AbbVie | 1 | $24 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
| Optinose US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$375
- DUPIXENT$284
- Haegarda$250
- Arikayce$158
- LEQVIO$134
- FASENRA$125
- Prolastin-C Liquid$125
- NUCALA$125
- TRELEGY ELLIPTA$121
- AIRSUPRA$109
How this compares
$11,949 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $46,909 |
| Spiriva RespimatTiotropium Bromide | 32 | $25,462 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $14,543 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $11,566 |
| Arnuity ElliptaFluticasone Furoate | 21 | $6,292 |
| Epinephrine | 35 | $6,029 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,890 |
| Qvar RedihalerBeclomethasone Dipropionate | 16 | $5,206 |
| Azelastine Hcl | 119 | $4,155 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,684 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $3,613 |
| Fluticasone Propionate | 124 | $2,216 |
| Ipratropium Bromide | 48 | $1,774 |
| Montelukast Sodium | 150 | $1,734 |
| Levocetirizine Dihydrochloride | 37 | $1,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,859 | $67,744102 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $36 | $31,35244 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $53 | $5,20616 claims |
| AstraZenecaSymbicort | $1,979 | $3,68416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Fort Walton Beach
- Brittany BrockFort Walton Beach$35K
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.